PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
Visit https://www.peervoice.com/JUW860 to view the entire programme with slides. After completing “Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?”, participants will be able to: Assess clinical trial data evaluating approved therapies in the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including chemotherapy, immunotherapy, and CAR T-cell therapy; and Formulate individualised treatment plans for patients with DLBCL upon progression to relapsed/refractory disease who are ineligible for stem-cell transplantation.